|
1
|
Alboni S, Van DIjk RM, Poggini S, Milior
G, Perrotta M, Drenth T, Brunello N, Wolfer DP, Limatola C, Amrein
I, et al: Fluoxetine effects on molecular, cellular and behavioral
endophenotypes of depression are driven by the living environment.
Mol Psychiatry. 22:552–561. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
World Health Organization: Mental
Disorders, 2022.
|
|
3
|
Isaac R, Boura-Halfon S, Gurevitch D,
Shainskaya A, Levkovitz Y and Zick Y: Selective serotonin reuptake
inhibitors (SSRIs) inhibit insulin secretion and action in
pancreatic β cells. J Biol Chem. 288:5682–5693. 2013.
|
|
4
|
Berardelli R, Margarito E, Ghiggia F, Picu
A, Balbo M, Bonelli L, Giordano R, Karamouzis I, Bo M, Ghigo E and
Arvat E: Neuroendocrine effects of citalopram, a selective
serotonin re-uptake inhibitor, during lifespan in humans. J
Endocrinol Invest. 33:657–662. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ruhé HG, Khoenkhoen SJ, Ottenhof KW,
Koeter MW, Mocking RJT and Schene AH: Longitudinal effects of the
SSRI paroxetine on salivary cortisol in major depressive disorder.
Psychoneuroendocrinology. 52:261–271. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Dubovicky M, Belovicova K, Csatlosova K
and Bogi E: Risks of using SSRI/SNRI antidepressants during
pregnancy and lactation. Interdiscip Toxicol. 10:30–34.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Avitsur R: Prenatal fluoxetine modifies
the behavioral and hormonal responses to stress in male mice: Role
for glucocorticoid insensitivity. Behav Pharmacol. 28:345–355.
2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Edinoff AN, Akuly HA, Hanna TA, Ochoa CO,
Patti SJ, Ghaffar YA, Kaye AD, Viswanath O, Urits I, Boyer AG, et
al: Selective serotonin reuptake inhibitors and adverse effects: A
narrative review. Neurol Int. 13:387–401. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Malagié I, Trillat AC, Jacquot C and
Gardier AM: Effects of acute fluoxetine on extracellular serotonin
levels in the raphe: An in vivo microdialysis study. Eur J
Pharmacol. 286:213–217. 1995.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Perez-Caballero L, Torres-Sanchez S, Bravo
L, Mico JA and Berrocoso E: Fluoxetine: A case history of its
discovery and preclinical development. Expert Opin Drug Discov.
9:567–578. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wille SMR, Cooreman SG, Neels HM and
Lambert WEE: Relevant issues in the monitoring and the toxicology
of antidepressants. Crit Rev Clin Lab Sci. 45:25–89.
2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Catterson ML and Preskorn SH:
Pharmacokinetics of selective serotonin reuptake inhibitors:
Clinical relevance. Pharmacol Toxicol. 78:203–208. 1996.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Benfield P, Heel RC and Lewis SP:
Fluoxetine. A review of its pharmacodynamic and pharmacokinetic
properties, and therapeutic efficacy in depressive illness. Drugs.
32:481–508. 1986.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Reis M, Aamo T, Spigset O and Ahlner J:
Serum concentrations of antidepressant drugs in a naturalistic
setting: Compilation based on a large therapeutic drug monitoring
database. Ther Drug Monit. 31:42–56. 2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gomez F and García-García L:
Anxiogenic-like effects of fluoxetine render adult male rats
vulnerable to the effects of a novel stress. Pharmacol Biochem
Behav. 153:32–44. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Alboni S, Benatti C, Montanari C, Tascedda
F and Brunello N: Chronic antidepressant treatments resulted in
altered expression of genes involved in inflammation in the rat
hypothalamus. Eur J Pharmacol. 721:158–167. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pawluski JL, Rayen I, Niessen NA,
Kristensen S, van Donkelaar EL, Balthazart J, Steinbusch HW and
Charlier TD: Developmental fluoxetine exposure differentially
alters central and peripheral measures of the HPA system in
adolescent male and female offspring. Neuroscience. 220:131–141.
2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Knaepen L, Rayen I, Charlier TD, Fillet M,
Houbart V, van Kleef M, Steinbusch HW, Patijn J, Tibboel D, Joosten
EA and Pawluski JL: Developmental fluoxetine exposure normalizes
the long-term effects of maternal stress on post-operative pain in
Sprague-Dawley rat offspring. PLoS One. 8(e57608)2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gemmel M, Hazlett M, Bögi E, De Lacalle S,
Hill LA, Kokras N, Hammond GL, Dalla C, Charlier TD and Pawluski
JL: Perinatal fluoxetine effects on social play, the HPA system,
and hippocampal plasticity in pre-adolescent male and female rats:
Interactions with pre-gestational maternal stress.
Psychoneuroendocrinology. 84:159–171. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Avitsur R, Grinshpahet R, Goren N,
Weinstein I, Kirshenboim O and Chlebowski N: Prenatal SSRI alters
the hormonal and behavioral responses to stress in female mice:
Possible role for glucocorticoid resistance. Horm Behav. 84:41–49.
2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ghaeli P, Shahsavand E, Mesbahi M, Kamkar
MZ, Sadeghi M and Dashti-Khavidaki S: Comparing the effects of
8-week treatment with fluoxetine and imipramine on fasting blood
glucose of patients with major depressive disorder. J Clin
Psychopharmacol. 24:386–388. 2004.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Pan SJ, Tan YL, Yao SW, Xin Y, Yang X, Liu
J and Xiong J: Fluoxetine induces lipid metabolism abnormalities by
acting on the liver in patients and mice with depression. Acta
Pharmacol Sin. 39:1463. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Masand PS and Gupta S: Long-term side
effects of newer-generation antidepressants: SSRIS, venlafaxine,
nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry.
14:175–182. 2002.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shahsavand Ananloo E, Ghaeli P, Kamkar MZ
and Sadeghi M: Comparing the effects of fluoxetine and imipramine
on total cholesterol, triglyceride, and weight in patients with
major depression. Daru. 21(4)2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Biagetti B and Corcoy R: Hypoglycemia
associated with fluoxetine treatment in a patient with type 1
diabetes. World J Clin Cases. 1:169–171. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Giri D, Price V, Yung Z, Didi M and
Senniappan S: Fluoxetine-induced hypoglycaemia in a patient with
congenital hyperinsulinism on lanreotide therapy. J Clin Res
Pediatr Endocrinol. 8:347–350. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Andersohn F, Schade R, Suissa S and Garbe
E: Long-term use of antidepressants for depressive disorders and
the risk of diabetes mellitus. Am J Psychiatry. 166:591–598.
2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sawka AM, Burgart V and Zimmerman D: Loss
of hypoglycemia awareness in an adolescent with type 1 diabetes
mellitus during treatment with fluoxetine hydrochloride. J Pediatr.
136:394–396. 2000.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Deeg MA and Lipkin EW: Hypoglycemia
associated with the use of fluoxetine. West J Med. 164:262–263.
1996.PubMed/NCBI
|
|
30
|
Preeti S, Jayaram SD and Chittaranjan A:
Sexual dysfunction in patients with antidepressant-treated anxiety
or depressive disorders: A pragmatic multivariable longitudinal
study. East Asian Arch Psychiatry. 28:9–16. 2018.PubMed/NCBI
|
|
31
|
AlBreiki M, Al Maqbali M, AlRisi K,
AlSinawi H, AlBalushi M and Al Zakwani W: Prevalence of
antidepressant-induced sexual dysfunction among psychiatric
outpatients attending a tertiary care hospital. Neurosciences
(Riyadh). 25:55–60. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Rowland D, McMahon CG, Abdo C, Chen J,
Jannini E, Waldinger MD and Ahn TY: Disorders of orgasm and
ejaculation in men. J Sex Med. 7:1668–1686. 2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Solomon R, Shvartsur R and Azab AN: The
association between psychotropic drug use and fertility problems
among male subjects. J Psychiatr Pract. 25:22–33. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Trenque T, Maura G, Herlem E, Vallet C,
Sole E, Auriche P and Drame M: Reports of sexual disorders related
to serotonin reuptake inhibitors in the French pharmacovigilance
database: An example of underreporting. Drug Saf. 36:515–519.
2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Relwani R, Berger D, Santoro N, Hickmon C,
Nihsen M, Zapantis A, Werner M, Polotsky AJ and Jindal S: Semen
parameters are unrelated to BMI but vary with SSRI use and prior
urological surgery. Reprod Sci. 18:391–397. 2011.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Safarinejad MR: Sperm DNA damage and semen
quality impairment after treatment with selective serotonin
reuptake inhibitors detected using semen analysis and sperm
chromatin structure assay. J Urol. 180:2124–2128. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Moore CJ, DeLong NE, Chan KA, Holloway AC,
Petrik JJ and Sloboda DM: Perinatal administration of a selective
serotonin reuptake inhibitor induces impairments in reproductive
function and follicular dynamics in female rat offspring. Reprod
Sci. 22:1297–1311. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ayala ME, Gonzáles A, Olivarez RM and
Aragón-Martínez A: Fluoxetine treatment of prepubertal male rats
uniformly diminishes sex hormone levels and, in a subpopulation of
animals, negatively affects sperm quality. Reprod Fertil Dev.
30:1329–1341. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
de Oliveira WM, de Sá IR, de Torres SM, de
Morais RN, Andrade AM, Maia FC, Tenorio BM and da Silva Junior VA:
Perinatal exposure to fluoxetine via placenta and lactation
inhibits the testicular development in male rat offspring. Syst
Biol Reprod Med. 59:244–250. 2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Elsedawi BF, Hussein Y, Sabry MA and Aziz
JA: Effect of fluoxetine on the testes of adult albino rats and the
possible protective role of curcumin. Anat Sci Int. 96:187–196.
2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Erdemir F, Atilgan D, Firat F, Markoc F,
Parlaktas BS and Sogut E: The effect of sertraline, paroxetine,
fluoxetine and escitalopram on testicular tissue and oxidative
stress parameters in rats. Int Braz J Urol. 40:100–108.
2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sakr HF, Abbas AM, Elsamanoudy AZ and
Ghoneim FM: Effect of fluoxetine and resveratrol on testicular
functions and oxidative stress in a rat model of chronic mild
stress-induced depression. J Physiol Pharmacol. 66:515–527.
2015.PubMed/NCBI
|
|
43
|
Câmara ML, Almeida TB, de Santi F,
Rodrigues BM, Cerri PS, Beltrame FL and Sasso-Cerri E:
Fluoxetine-induced androgenic failure impairs the seminiferous
tubules integrity and increases ubiquitin carboxyl-terminal
hydrolase L1 (UCHL1): Possible androgenic control of UCHL1 in germ
cell death? Biomed Pharmacother. 109:1126–1139. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Monteiro Filho WO, de Torres SM, Amorim
MJ, Andrade AJ, de Morais RN, Tenorio BM and da Silva Junior VA:
Fluoxetine induces changes in the testicle and testosterone in
adult male rats exposed via placenta and lactation. Syst Biol
Reprod Med. 60:274–281. 2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
dos Santos AH, Vieira ML, de Azevedo Camin
N, Anselmo-Franci JA, Ceravolo GS, Pelosi GG, Moreira EG, Kiss AC,
Mesquita Sde F and Gerardin DC: In utero and lactational exposure
to fluoxetine delays puberty onset in female rats offspring. Reprod
Toxicol. 62:1–8. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Romero-Reyes J, Cárdenas M,
Damián-Matsumura P, Domínguez R and Ayala ME: Inhibition of
serotonin reuptake in the prepubertal rat ovary by fluoxetine and
effects on ovarian functions. Reprod Toxicol. 59:80–88.
2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
De Long NE, Hyslop JR, Raha S, Hardy DB
and Holloway AC: Fluoxetine-induced pancreatic beta cell
dysfunction: New insight into the benefits of folic acid in the
treatment of depression. J Affect Disord. 166:6–13. 2014.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Cataldo LR, Cortés VA, Mizgier ML, Aranda
E, Mezzano D, Olmos P, Galgani JE, Suazo J and Santos JL:
Fluoxetine impairs insulin secretion without modifying
extracellular serotonin levels in MIN6 β-cells. Exp Clin Endocrinol
Diabetes. 123:473–478. 2015.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Grankvist K, Marklund SL and Täljedal IB:
CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and
glutathione peroxidase in pancreatic islets and other tissues in
the mouse. Biochem J. 199:393–398. 1981.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Lenzen S, Drinkgern J and Tiedge M: Low
antioxidant enzyme gene expression in pancreatic islets compared
with various other mouse tissues. Free Radic Biol Med. 20:463–466.
1996.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Elmorsy E, Al-Ghafari A, Helaly ANM, Hisab
AS, Oehrle B and Smith PA: Editor's highlight: Therapeutic
concentrations of antidepressants inhibit pancreatic beta-cell
function via mitochondrial complex inhibition. Toxicol Sci.
158:286–301. 2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Dissanayake WC, Sorrenson B and Shepherd
PR: The role of adherens junction proteins in the regulation of
insulin secretion. Biosci Rep. 38(BSR20170989)2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Chang HY, Chen SL, Shen MR, Kung ML,
Chuang LM and Chen YW: Selective serotonin reuptake inhibitor,
fluoxetine, impairs E-cadherin-mediated cell adhesion and alters
calcium homeostasis in pancreatic beta cells. Sci Rep.
7(3515)2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Tharmaraja T, Stahl D, Hopkins CWP,
Persaud SJ, Jones PM, Ismail K and Moulton CD: The association
between selective serotonin reuptake inhibitors and glycemia: A
systematic review and meta-analysis of randomized controlled
trials. Psychosom Med. 81:570–583. 2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Ye Z, Chen L, Yang Z, Li Q, Huang Y, He M,
Zhang S, Zhang Z, Wang X, Zhao W, et al: Metabolic effects of
fluoxetine in adults with type 2 diabetes mellitus: A meta-analysis
of randomized placebo-controlled trials. PLoS One.
6(e21551)2011.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Liu B, Ruz-Maldonado I, Toczyska K,
Olaniru OE, Zariwala MG, Hopkins D, Zhao M and Persaud SJ: The
selective serotonin reuptake inhibitor fluoxetine has direct
effects on beta cells, promoting insulin secretion and increasing
beta-cell mass. Diabetes Obes Metab. 24:2038–2050. 2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Flandreau EI, Bourke CH, Ressler KJ, Vale
WW, Nemeroff CB and Owens MJ: Escitalopram alters gene expression
and HPA axis reactivity in rats following chronic overexpression of
corticotropin-releasing factor from the central amygdala.
Psychoneuroendocrinology. 38:1349–1361. 2013.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Hansen CH, Larsen LW, Sørensen AM,
Halling-Sørensen B and Styrishave B: The six most widely used
selective serotonin reuptake inhibitors decrease androgens and
increase estrogens in the H295R cell line. Toxicol In Vitro.
41:1–11. 2017.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Nikisch G, Mathé AA, Czernik A, Thiele J,
Bohner J, Eap CB, Agren H and Baumann P: Long-term citalopram
administration reduces responsiveness of HPA axis in patients with
major depression: Relationship with S-citalopram concentrations in
plasma and cerebrospinal fluid (CSF) and clinical response.
Psychopharmacology (Berl). 181:751–760. 2005.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Jørgensen H, Knigge U, Kjær A, Møller M
and Warberg J: Serotonergic stimulation of corticotropin-releasing
hormone and pro-opiomelanocortin gene expression. J
Neuroendocrinol. 14:788–795. 2002.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Durell N, Franks R, Coon S, Cowart K and
Carris NW: Effect of antidepressants on glucagon-like peptide-1
receptor agonist-related weight loss. J Pharm Technol. 38:283–288.
2022.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Ilgin S, Kilic G, Baysal M, Kilic V,
Korkut B, Ucarcan S and Atli O: Citalopram induces reproductive
toxicity in male rats. Birth Defects Res. 109:475–485.
2017.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Prasad P, Ogawa S and Parhar IS: Serotonin
reuptake inhibitor citalopram inhibits GnRH synthesis and
spermatogenesis in the male zebrafish. Biol Reprod.
93(102)2015.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Koyuncu H, Serefoglu EC, Yencilek E,
Atalay H, Akbas NB and Sarıca K: Escitalopram treatment for
premature ejaculation has a negative effect on semen parameters.
Int J Impot Res. 23:257–261. 2011.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Sanchez C, Reines EH and Montgomery SA: A
comparative review of escitalopram, paroxetine, and sertraline: Are
they all alike? Int Clin Psychopharmacol. 29:185–196.
2014.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Pastoor D and Gobburu J: Clinical
pharmacology review of escitalopram for the treatment of
depression. Expert Opin Drug Metab Toxicol. 10:121–128.
2014.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Wu C, Gong WG, Wang YJ, Sun JJ, Zhou H,
Zhang ZJ and Ren QG: Escitalopram alleviates stress-induced
Alzheimer's disease-like tau pathologies and cognitive deficits by
reducing hypothalamic-pituitary-adrenal axis reactivity and
insulin/GSK-3β signal pathway activity. Neurobiol Aging.
67:137–147. 2018.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Benatti C, Alboni S, Blom JMC, Mendlewicz
J, Tascedda F and Brunello N: Molecular changes associated with
escitalopram response in a stress-based model of depression.
Psychoneuroendocrinology. 87:74–82. 2018.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Ronaldson A, Carvalho LA, Kostich K,
Lazzarino AI, Urbanova L and Steptoe A: The effects of six-day SSRI
administration on diurnal cortisol secretion in healthy volunteers.
Psychopharmacology (Berl). 235:3415–3422. 2018.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Tafet GE and Nemeroff CB: Pharmacological
treatment of anxiety disorders: The role of the HPA axis. Front
Psychiatry. 11(443)2020.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Knorr U, Vinberg M, Gether U, Winkel P,
Gluud C, Wetterslev J and Kessing LV: The effect of escitalopram
versus placebo on perceived stress and salivary cortisol in healthy
first-degree relatives of patients with depression-A randomised
trial. Psychiatry Res. 200:354–360. 2012.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Bourke CH, Stowe ZN, Neigh GN, Olson DE
and Owens MJ: Prenatal exposure to escitalopram and/or stress in
rats produces limited effects on endocrine, behavioral, or gene
expression measures in adult male rats. Neurotoxicol Teratol.
39:100–109. 2013.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Schroeder JW, Smith AK, Brennan PA,
Conneely KN, Kilaru V, Knight BT, Newport DJ, Cubells JF and Stowe
ZN: DNA methylation in neonates born to women receiving psychiatric
care. Epigenetics. 7:409–414. 2012.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Nevels RM, Gontkovsky ST and Williams BE:
Paroxetine-the antidepressant from hell? Probably not, but caution
required. Psychopharmacol Bull. 46:77–104. 2016.PubMed/NCBI
|
|
75
|
Bourin M, Chue P and Guillon Y:
Paroxetine: A review. CNS Drug Rev. 7:25–47. 2001.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Jacobsen NW, Hansen CH, Nellemann C,
Styrishave B and Halling-Sørensen B: Effects of selective serotonin
reuptake inhibitors on three sex steroids in two versions of the
aromatase enzyme inhibition assay and in the H295R cell assay.
Toxicol In Vitro. 29:1729–1735. 2015.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Jing E and Straw-Wilson K: Sexual
dysfunction in selective serotonin reuptake inhibitors (SSRIs) and
potential solutions: A narrative literature review. Ment Health
Clin. 6:191–196. 2016.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Ulker N, Yardimci A, Kaya Tektemur N,
Colakoglu N, Ozcan M, Canpolat S and Kelestimur H: Chronic exposure
to paroxetine or bupropion modulates the pubertal maturation and
the reproductive system in female rats. Reprod Biol. 20:154–163.
2020.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Singh HK and Saadabadi A: Sertraline. In:
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing,
2023.
|
|
80
|
Fuller RW, Hemrick-Luecke SK, Littlefield
ES and Audia JE: Comparison of desmethylsertraline with sertraline
as a monoamine uptake inhibitor in vivo. Prog Neuropsychopharmacol
Biol Psychiatry. 19:135–149. 1995.PubMed/NCBI View Article : Google Scholar
|
|
81
|
López-Muñoz F and Alamo C: Active
metabolites as antidepressant drugs: The role of norquetiapine in
the mechanism of action of quetiapine in the treatment of mood
disorders. Front Psychiatry. 4(102)2013.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Rothmore J: Antidepressant-induced sexual
dysfunction. Med J Aust. 212:329–334. 2020.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Lyons DJ, Ammari R, Hellysaz A and
Broberger C: Serotonin and antidepressant SSRIs inhibit rat
neuroendocrine dopamine neurons: Parallel actions in the
lactotrophic axis. J Neurosci. 36:7392–7406. 2016.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Munkboel CH, Larsen LW, Weisser JJ,
Møbjerg Kristensen D and Styrishave B: Sertraline suppresses testis
and adrenal steroid production and steroidogenic gene expression
while increasing LH in plasma of male rats resulting in
compensatory hypogonadism. Toxicol Sci. 163:609–619.
2018.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Gregorian RS, Golden KA, Bahce A, Goodman
C, Kwong WJ and Khan ZM: Antidepressant-induced sexual dysfunction.
Ann Pharmacother. 36:1577–1589. 2002.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Hamdi H: The preventive role of wheat germ
oil against sertraline-induced testicular damage in male albino
rats. Andrologia. 51(e13369)2019.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Van der Paal J, Neyts EC, Verlackt CCW and
Bogaerts A: Effect of lipid peroxidation on membrane permeability
of cancer and normal cells subjected to oxidative stress. Chem Sci.
7:489–498. 2016.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Atli O, Baysal M, Aydogan-Kilic G, Kilic
V, Ucarcan S, Karaduman B and Ilgin S: Sertraline-induced
reproductive toxicity in male rats: Evaluation of possible
underlying mechanisms. Asian J Androl. 19:672–679. 2017.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Pinney SE and Simmons RA: Epigenetic
mechanisms in the development of type 2 diabetes. Trends Endocrinol
Metab. 21:223–229. 2010.PubMed/NCBI View Article : Google Scholar
|
|
90
|
De Long NE, Gutgesell MK, Petrik JJ and
Holloway AC: Fetal exposure to sertraline hydrochloride impairs
pancreatic β-cell development. Endocrinology. 156:1952–1957.
2015.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Benfield P and Ward A: Fluvoxamine. A
review of its pharmacodynamic and pharmacokinetic properties, and
therapeutic efficacy in depressive illness. Drugs. 32:313–334.
1986.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Sukhatme VP, Reiersen AM, Vayttaden SJ and
Sukhatme VV: Fluvoxamine: A review of its mechanism of action and
its role in COVID-19. Front Pharmacol. 12(652688)2021.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Anderson IM, Deakin JF and Miller HE: The
effect of chronic fluvoxamine on hormonal and psychological
responses to buspirone in normal volunteers. Psychopharmacology
(Berl). 128:74–82. 1996.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Rinne T, de Kloet ER, Wouters L, Goekoop
JG, de Rijk RH and van den Brink W: Fluvoxamine reduces
responsiveness of HPA axis in adult female BPD patients with a
history of sustained childhood abuse. Neuropsychopharmacol.
28:126–132. 2003.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Oishi A, Mochizuki Y, Otsu R and Inaba N:
Pilot study of fluvoxamine treatment for climacteric symptoms in
Japanese women. Biopsychosoc Med. 1(12)2007.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Ishibashi Y, Izumo N, Iwata K, Morikawa T,
Kameyama T, Watanabe Y, Manabe T and Matsuzaki H: Research and
Report Fluvoxamine reverses estrogen-dependent decline in voluntary
activities and decreased amygdala levels of serotonin in
ovariectomized rats. J Brain Sci. 46:5–19. 2016.
|
|
97
|
Cella S, Pen̄alva A, Locatelli V, Novelli
A, Cocchi D and Müller EE: Neuroendocrine studies with fluvoxamine:
Animal data. Br J Clin Pharmacol. 15 (Suppl 3):357S–364S.
1983.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Hosoi T, Miyahara T, Kayano T, Yokoyama S
and Ozawa K: Fluvoxamine attenuated endoplasmic reticulum
stress-induced leptin resistance. Front Endocrinol (Lausanne).
3(12)2012.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Obradovic M, Sudar-Milovanovic E, Soskic
S, Essack M, Arya S, Stewart AJ, Gojobori T and Isenovic ER: Leptin
and obesity: Role and clinical implication. Front Endocrinol
(Lausanne). 12(585887)2021.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Kotkowska Z and Strzelecki D: Depression
and autoimmune hypothyroidism-their relationship and the effects of
treating psychiatric and thyroid disorders on changes in clinical
and biochemical parameters including BDNF and other cytokines-A
systematic review. Pharmaceuticals (Basel). 15(391)2022.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Caye A, Pilz LK, Maia AL, Hidalgo MP,
Furukawa TA and Kieling C: The impact of selective serotonin
reuptake inhibitors on the thyroid function among patients with
major depressive disorder: A systematic review and meta-analysis.
Eur Neuropsychopharmacol. 33:139–145. 2020.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Baumgartner A, Dubeyko M, Campos-Barros A,
Eravci M and Meinhold H: Subchronic administration of fluoxetine to
rats affects triiodothyronine production and deiodination in
regions of the cortex and in the limbic forebrain. Brain Res.
635:68–74. 1994.PubMed/NCBI View Article : Google Scholar
|
|
103
|
de Carvalho GA, Bahls SC, Boeving A and
Graf H: Effects of selective serotonin reuptake inhibitors on
thyroid function in depressed patients with primary hypothyroidism
or normal thyroid function. Thyroid. 19:691–697. 2009.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Eker SS, Akkaya C, Ersoy C, Sarandol A and
Kirli S: Reversible escitalopram-induced hypothyroidism. Gen Hosp
Psychiatry. 32:559.e5–e7. 2010.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Takahashi M, Sawayama E, Sawayama T and
Miyaoka H: Reversible paroxetine-induced symptomatic
hypothyroidism. Pharmacopsychiatry. 40:201–202. 2007.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Cooper-Kazaz R and Lerer B: Efficacy and
safety of triiodothyronine supplementation in patients with major
depressive disorder treated with specific serotonin reuptake
inhibitors. Int J Neuropsychopharmacol. 11:685–699. 2008.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Hage M and Azar ST: The link between
thyroid function and depression. J Thyroid Res.
2012(590648)2012.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Jackson IM: Does thyroid hormone have a
role as adjunctive therapy in depression? Thyroid. 6:63–7.
1996.PubMed/NCBI View Article : Google Scholar
|
